Novartis Reports New Data of Kesimpta (ofatumumab) in ALITHIOS Study for Multiple Sclerosis
Shots: The P-II study involves assessing of four doses of GIP/GLP-1 RA, LY3298176 (1 mg, 5 mg, 10 mg, 15 mg) vs PBO and dulaglutide 1.5 mg in 200 patients with Type 2 Diabetes for 26 weeks P-II study results (GIP/GLP-1 RA (5/10/15 mg) vs dulaglutide and PBO): HbA1c reduction (-1.6% @5 mg, -2.0% @10 […]Read More
